Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
AC Immune SA
AC Immune SA
(ACIU)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
No data
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Fluorodopa f-18
ovarian neoplasms
,
neoplasms
,
non-small-cell lung carcinoma
,
triple negative breast neoplasms
,
hepatocellular carcinoma
,
stomach neoplasms
,
melanoma
,
small cell lung carcinoma
,
cholangiocarcinoma
,
merkel cell carcinoma
,
mesothelioma
,
large b-cell lymphoma diffuse
,
non-hodgkin lymphoma
,
b-cell lymphoma
,
burkitt lymphoma
Gilvetmab
urologic neoplasms
,
urethral neoplasms
,
transitional cell carcinoma
,
ureteral neoplasms
,
pelvic neoplasms
,
prostatic neoplasms
,
urinary bladder neoplasms
Bevifimod
hypersensitivity
,
peanut hypersensitivity
Fludeoxyglucose f-18
healthy volunteers/patients
,
non-small-cell lung carcinoma
,
alzheimer disease
,
carcinoma
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
sarcoma
,
gastrointestinal stromal tumors
,
breast neoplasms
,
pancreatic ductal carcinoma
,
pancreatic neoplasms
,
triple negative breast neoplasms
,
small cell lung carcinoma
,
glioblastoma
,
disease
,
prostatic neoplasms
,
coronary artery disease
,
atherosclerosis
,
inflammation
,
atherosclerotic plaque
,
cardiovascular diseases
,
molecular imaging
,
large b-cell lymphoma diffuse
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use